Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
O'Connor
Christopher M
CM
Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27705, USA. oconn002@mc.duke.edu
Gattis
Wendy A
WA
Adams
Kirkwood F
KF
Shah
Monica R
MR
Frey
Aline
A
Gheorghiade
Mihai
M
D004311:Double-Blind Method; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use*; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000502:physiology; D012008:Recurrence; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D011725:Pyridines; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D013777:Tetrazoles; D014665:Vasodilator Agents; C120582:tezosentan